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Leptin inhibition of bone mass accrual requires the
integrity of specific hypothalamic neurons but not
expression of its receptor on these neurons. The
same is true for its regulation of appetite and energy
expenditure. This suggests that leptin acts elsewhere
in the brain to achieve these three functions.We show
here that brainstem-derived serotonin (BDS) favors
bone mass accrual following its binding to Htr2c
receptors on ventromedial hypothalamic neurons
and appetite via Htr1a and 2b receptors on arcuate
neurons. Leptin inhibits these functionsand increases
energy expenditure because it reduces serotonin
synthesis and firing of serotonergic neurons. Accord-
ingly, while abrogating BDS synthesis corrects the
bone, appetite and energy expenditure phenotypes
caused by leptin deficiency, inactivation of the leptin
receptor in serotonergic neurons recapitulates them
fully. This study modifies the map of leptin signaling
in the brain and identifies a molecular basis for the
common regulation of bone and energymetabolisms.
For a video summary of this article, see the
PaperFlick file with the Supplemental Data available
online.
INTRODUCTION
Leptin is an adipocyte-derived hormone that regulates a broad
spectrum of homeostatic functions following its binding to the
signaling form of its receptor, ObRb, present on neurons of the
central nervous system (Friedman and Halaas, 1998; Spiegel-976 Cell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc.man and Flier, 2001). It is widely assumed that the hypothal-
amus, where ObRb is expressed in several nuclei, is the main
site where leptin acts in the brain (Elmquist, 2000).
One homeostatic function regulated by leptin in rodents,
sheep and humans is bone remodeling, the mechanismwhereby
vertebrates renew their bones during adulthood (Karsenty, 2006;
Pogoda et al., 2006). Leptin regulates, only through a central
relay, both phases of this process, resorption and formation
(Ducy et al., 2000; Shi et al., 2008). One mediator linking leptin
signaling in the brain to bone remodeling is the sympathetic
tone which inhibits bone formation and favors bone resorption
through the b2 adrenergic receptor (Adrb2) expressed in osteo-
blasts (Elefteriou et al., 2005; Takeda et al., 2002). Hence,
sympathetic activity can be used as a readout of leptin regulation
of bone mass.
The leptin-dependent central control of bone mass raises the
question of the identity of the neurons mediating it. Chemical
lesioning experiments performed in both WT and leptin-deficient
(ob/ob) mice followed by leptin intracerebroventricular (ICV) infu-
sion provided compelling evidence that, to regulate bone mass,
leptin requires the integrity of neurons of the ventromedial hypo-
thalamic (VMH) nuclei which in turn influence sympathetic activity
(Takeda et al., 2002). Surprisingly however, VMH-specific dele-
tion of ObRb does not affect bone mass (Balthasar et al., 2004).
At least two interpretations of these experiments can be
proposed. The first one is that they are contradicting each other
and that, since chemical lesioning is less precise than cell-
specific gene deletion, results obtained using the former tech-
nique are not reliable (Waddington et al., 2007). A second, more
literal, interpretation views these two experiments as comple-
mentary and simply states that VMH neurons are necessary for
leptin to regulate bonemassbut signaling throughObRbon these
neurons is not.
This latter interpretation gains further support if one looks at
another function regulated centrally by leptin: appetite. Genetic
inactivation of ObRb in all neurons and chemical destruction of
the arcuate nuclei of hypothalamus increases appetite (Cohen
et al., 2001), yet inactivation of ObRb selectively in arcuate,
VMH or in both nuclei does not when mice are fed a normal diet
(Balthasar et al., 2004). This inconsistency echoes the one noted
above for the regulation of bone mass. Together they raise the
prospect that leptin may first act elsewhere in the brain to affect
synthesis of neuromediator(s) that in turn influences bone mass
and energy metabolism by signaling to hypothalamic neurons.
Serotonin is an indoleamine produced in enterochromaffin
cells of the duodenum and in serotonergic neurons of brainstem
that does not cross the blood brain barrier (Mann et al., 1992).
Thus, it is de facto a molecule with two distinct functional identi-
ties depending on its site of synthesis: a hormone when made in
the gut and a neurotransmitter when made in the brain (Walther
et al., 2003; Yadav et al., 2008). Although brain-derived serotonin
(BDS) has many known roles (Heath and Hen, 1995) its potential
function as a regulator of bone mass accrual or other homeo-
static processes has not been thoroughly examined yet. This is
an important question to address for several reasons. First, the
critical role exerted by gut-derived serotonin on bone formation
(Yadav et al., 2008) raises questions regarding the role BDS may
have in this process. Additionally, in invertebrates where it has
been tested genetically, serotonin strongly enhances appetite
(Horvitz et al., 1982; Srinivasan et al., 2008).
Hereweshowthat, unlike leptin,BDS favorsbonemassaccrual
and appetite, and decreases energy expenditure following its
binding to distinct receptors located on two different hypotha-
lamic nuclei. Cell-specific gene deletion of the leptin receptor
show that leptin regulation of these functions occurs by inhibiting
serotonin synthesis in neurons of the brainstem. These results
reveal a different map of leptin action in the brain, expand the
importance of BDS in physiology, they also identify a molecular
basis for the common central control of bone mass and appetite.
RESULTS
Low Bone Mass in Mice Deprived of Serotonin
in the Brain
Serotonin synthesis is initiated by hydroxylation of tryptophan,
a rate-limiting reaction performed by the enzyme tryptophan
hydroxylase 2 (Tph2) in the brain (Walther et al., 2003). To deter-
mine whether BDS affects bone mass we disrupted Tph2 by
inserting LacZ in its locus (Figure S1A) and first used this allele
to study Tph2 pattern of expression.
The location of serotonergic neurons in the present study was
defined according to Jensen et al. (Jensen et al., 2008) as
follows: Dorsal raphe (B4, B6 and B7), median raphe (B5, B8
and B9) and caudal raphe (B1, B2 and B3) nuclei. Together these
neurons will be referred thereafter as serotonergic neurons of
the brainstem in this manuscript. b-galactosidase staining of the
whole brain showed that during embryonic development Tph2
expression was detected as early as E12.5 in neurons of the
dorsal and median raphe nuclei in the brainstem (Figure 1A
and data not shown). At E14.5, 15.5, and 18.5, b-galactosidase
staining was also detected in neurons of the caudal raphe nuclei
of the brainstem (Figures 1A and 1B) but not in other areas of the
brain or in peripheral tissues (Figures S1B–S1D). To determinewhether b-galactosidase staining is a faithful representation of
Tph2 endogenous expression we performed in situ hybridization
and coimmunolocalization of Tph2 and b-galactosidase. These
experiments revealed a tight concordance between Tph2 ex-
pression and b-galactosidase staining (Figure 1C). After birth,
Tph2 expression measured by real-time PCR was four orders of
magnitude higher in the brainstem than in other parts of the brain
or in peripheral tissues (Figure 1D). Based on these criteria, Tph2
expression is specific to serotonergic neurons of the brainstem.
Tph2/ mice were born at the expected Mendelian ratio,
had a normal size and appearance and were normally fertile
(Figure 1H and data not shown). The near complete absence of
detectable serotonin in the brain of Tph2/ mice verified that
we had successfully inactivated this gene and was consistent
with the fact that Tph1 expression in the brain was not enhanced,
at least post-natally, by the Tph2 deletion (Figures 1E and 1F).
Conversely, blood serotonin levels were normal in Tph2/
mice (Figure 1G). Thus the Tph2/ mouse is an animal model
lacking serotonin selectively in the brain. Serum levels of leptin,
insulin, corticosterone and T4 as well as body length were also
normal in 3-month-old Tph2/ animals (Figures 1H and S1E).
To assess the influence of BDS on bone remodeling histolog-
ical, histomorphometric and microcomputed tomography (mCT)
analyses of bones were performed in 4-, 6- and 12-week-old
wild-type (WT) and Tph2/ mice. The absence of serotonin in
the brain resulted, at all time points, in a severe low bone mass
phenotype affecting axial (vertebrae) and appendicular (long
bones) skeleton while bone length and width were unaffected
(Figures 2A–2D and data not shown). Three-month-old Tph2+/
mice also displayed a decrease in bone mass, albeit milder (Fig-
ure 2A). This phenotype was secondary to a decrease in bone
formation parameters (osteoblast numbers and bone formation
rate) and to an increase in bone resorption parameters (osteo-
clast surface and circulating levels of deoxypridinoline [Dpd],
a degradation product of type I Collagen and a biomarker of
bone resorption [Eyre et al., 1988]) (Figures 2A and 2E). Bone
mineralization was normal in Tph2/ mice (Figure S2). These
results demonstrate that BDS is a positive and powerful
regulator of bone mass accrual acting on both arms of bone
remodeling. Since serotonin does not cross the blood brain
barrier these observations provide a rare example of a regulation
of bone mass by a neuromediator.
The Influence of Brain-Derived Serotonin on Bone Mass
Prevails over the One of Gut-Derived Serotonin
That serotonin exerts opposite influences on bone remodeling
depending on its site of synthesis was unexpected. Since BDS
accounts for only 5% of total serotonin we asked what was its
actual contribution to the overall regulation of bonemass accrual
by serotonin. To that end we generated mice unable to synthe-
size serotonin anywhere in their body by inactivating both Tph1
and Tph2 (Figures 3A and 3B). Tph1/;Tph2/ mice were
born at the expected Mendelian ratio and had normal size and
life span (data not shown). To our surprise, like the Tph2/
mice, Tph1/;Tph2/ mice displayed a low bone mass
secondary to a decrease in bone formation and to an increase
in bone resorption parameters and affecting the axial and appen-
dicular skeleton (Figure 3C and data not shown). By showing thatCell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc. 977
Figure 1. Generation of Tph2/ Mice
(A) b-Galactosidase staining in the mouse brain during embryonic (E12.5-18.5) development. A, anterior; P, posterior.
(B) Localization of Tph2-expressing neurons in the dorsal (DR; from Bregma 4.04 to 5.49), median (MR; from Bregma 4.04 to 4.48), and caudal raphe
(CR; from Bregma 4.84 to 7.48) in coronal sections of a mouse brain.
(C) Tph2 expression by in situ hybridization, b-galactosidase staining, and coimmunolocalization in Tph2LacZ/+ mice. Arrowheads indicate Tph2/ b-Gal double
positive cells.
(D) Real-time PCR (qPCR) analysis of Tph2 expression in tissues of WT mice.
(E) qPCR analysis of Tph2 expression in brainstem (BS) and duodenum (Duod) of WT and Tph2/ mice.
(F) HPLC analysis of serotonin levels in different regions of brain in WT, Tph2+/ and Tph2/ mice.
(G) Serum serotonin levels in WT, Tph2+/ and Tph2/ mice.
(H) Mean litter size, serum biochemistry, and body length in WT, Tph2+/, and Tph2/ mice (n is indicated in superscript above each value).
For all panels (except [F]) * p < 0.05; ** p < 0.01 (Student’s t test). Error bars represent the SEM. For (F): one-way ANOVA, Newman-Keuls test; different letters on
two or more bars indicate significant differences between the respective groups (p < 0.05).the influence of BDS on bone remodeling prevails over the one
exerted by gut-derived serotonin even though it accounts for
only 5% of the total pool of serotonin this experiment under-
scored the importance of BDS in the regulation of bone mass
and was an incentive to elucidate its mode of action.
Sympathetic Mediation of Brain-Derived Serotonin
Regulation of Bone Mass
The decrease in bone formation and the increase in bone resorp-
tion seen in Tph2/mice is themirror image of what is observed978 Cell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc.in mice lacking the b2 adrenergic receptor (Adrb2/mice) (Elef-
teriou et al., 2005). This feature suggested that the bone pheno-
type of the mice lacking serotonin in the brain could be
secondary to an increase in sympathetic signaling in osteo-
blasts. That norepinephrine content in the brain, epinephrine
elimination in the urine and Ucp1 expression in brown fat, three
markers of the sympathetic tone, were all markedly increased in
Tph2+/, Tph2/, and Tph1/;Tph2/mice at 6 and 12 weeks
of age supported this hypothesis (Figures 3D–3F and S3). We
also generated Tph2/ mice in which one allele of Adrb2 had
Figure 2. Low Bone Mass in Tph2/ Mice
(A and B) Histological analysis of vertebrae (A) and long bones (B) of WT, Tph2+/, and Tph2/ mice. Mineralized bone matrix is stained in black by von Kossa
reagent. Histomorphometric parameters. BV/TV%, bone volume over trabecular volume; Nb.Ob/T.Ar., number of osteoblasts per trabecular area; BFR, bone
formation rate; OcS/BS, osteoclast surface per bone surface.
(C) BV/TV% analysis in WT and Tph2/ mice at 4, 6, 8, and 12 weeks after birth.
(D) Lower bone density in long bones of 12-week-old Tph2/ mice by mCT analysis along with lower Tb. Th (trabecular thickness) and decreased connectivity
density (Conn.D).
(E) Serum Dpd levels in WT and Tph2/ mice.
For all panels: * p < 0.05; ** p < 0.01. Error bars represent the SEM.been inactivated (Figures 3F and 3G). We removed one copy of
this gene because Adrb2 is the only adrenergic receptor ex-
pressed in osteoblasts (Takeda et al., 2002). Tph2/;Adrb2+/
mice had normal bone formation and bone resorption parame-
ters and a normal bone mass, the same was true for Tph2/;
Adrb2/ mice (Figure 3G and data not shown). These results
indicate that the regulation of bone mass accrual by BDS occurs
by decreasing the sympathetic tone.
Brain-Derived Serotonin Regulates Bone Mass through
the Hypothalamus
Since the sympathetic regulation of bone mass requires the
integrity of the VMH neurons of the hypothalamus (Takeda
et al., 2002) we next asked whether the BDS regulation of
bone mass also occurs through a VMH relay.
To search for anatomical connections between Tph2-express-
ing and hypothalamic neurons we used the Rosa26R-Ecfp mice
(Srinivas et al., 2001). In this latter mouse model the Ecfp
(Enhanced Cyan fluorescent protein) reporter gene containing
a floxed transcriptional blocker cassette inserted between the
transcription start site and the ATG is placed downstream ofthe Rosa26 promoter. Thus, Ecfp can only be expressed after
Cre-mediated deletion of the transcriptional blocker. We
crossed Rosa26R-Ecfp mice with Sert-Cre transgenic mice
that express Cre only in Tph2-expressing neurons (Zhuang
et al., 2005). Ecfp immunostaining in Sert-Cre; Rosa26R-Ecfp
mice showed that axons emanating from Tph2-expressing
neurons of the brainstem projected to the hypothalamus
(Figure 4A) and in situ hybridization performed on adjacent
sections demonstrated that those axonal projections reached
Sf1-expressing VMH neurons (Figure 4A). These findings were
confirmed by fluorescent dextran tracing. Anterograde and
retrograde labeling in Tph2+/ mice showed that VMH neurons
were targeted by neuronal projections emanating from Tph2-
expressing neurons in the brainstem (Figures 4B, 4C, S4A, and
S4B). This morphological data suggesting that serotonin signals
in neurons of the VMH nuclei was an incentive to search for sero-
tonin receptor(s) on these neurons.
Real-time PCR analysis revealed that among the 14 serotonin
receptors Htr2c was by far the most highly expressed in the
hypothalamus albeit it was not the only one (Figure 4D) and
double fluorescent in situ hybridization experiments showedCell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc. 979
Figure 3. Brain-Derived Serotonin Inhibits Sympathetic Activity
(A and B) HPLC analysis of serotonin levels in different regions of brain and serum serotonin levels in WT and Tph1/;Tph2/ mice.
(C) Histomorphometric analysis of vertebrae of WT, Tph1/, Tph2/, and Tph1/;Tph2/ mice.
(D) Epinephrine levels in WT, Tph2+/, Tph2/, and Tph1/;Tph2/ mice.
(E) qPCR analysis of Ucp1 expression in brown adipose tissue of WT, Tph2+/, Tph2/, and Tph1/;Tph2/ mice.
(F) Epinephrine levels in the urine of WT, Tph2/, and Tph2/;Adrb2+/ mice.
(G) Histomorphometric analysis of vertebrae of WT, Tph2/, and Tph2/;Adrb2+/ mice.
For all panels (except [D] and [E]): * p < 0.05; ** p < 0.01 (Student’s t test). Error bars represent SEM. For (D) and (E): one-way ANOVA, Newman-Keuls test. Different
letters on two or more bars indicate significant differences between the respective groups (p < 0.05).that Htr2c was expressed in Sf1-expressing VMH and in Pomc-
expressing arcuate neurons (Pasqualetti et al., 1998) (Figures 4E
and S4C). Moreover, Ecfp-positive neuronal arborizations origi-
nating from serotonergic neurons of the brainstem project pref-
erentially to the anterior part of the VMH nucleus where Htr2c
is expressed at its highest level (from Bregma 1.06 mm to
1.34 mm; Figure 4A, right panel). To determine the importance
of serotonin signaling through Htr2c in the regulation of bone
mass we first analyzed mice lacking Htr2c in all cells (Htr2c/
mice). Since Htr2c/ mice develop an increase in food intake
and adiposity beyond 14 week of age (Tecott et al., 1995), we
analyzed 6- and 12-week-old animals after verifying that at those
ages appetite, energy expenditure, body weight, fat pad weights
and hormonal profiles were identical in Htr2c/ and WT mice
(Figures S4D–S4H).
Histological analyses uncovered in both 6- and 12-week-old
Htr2c/ mice a severe low bone mass phenotype secondary
to a decrease in the number of osteoblasts and bone formation
rate, and to an increase in the number of osteoclasts and bone
resorption parameters (Figure 4Fanddata not shown).Moreover,
Ucp1 expression in brown fat and urinary elimination of epineph-980 Cell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc.rine were both significantly higher in Htr2c/mice revealing the
existence of a high sympathetic activity (Figures 4G and 4H).
Thus, both in terms of bone remodeling parameters and sympa-
thetic tone, Htr2c/ mice are a phenocopy of Tph2/ mice at
time points when no metabolic abnormalities could be found.
To establish that it is by signaling through Htr2c that BDS regu-
lates bone mass we generated compound mutant mice lacking
one allele of Tph2 and one allele of Htr2c (Tph2+/;Htr2c+/
mice). These latter mutant mice presented at 6 and 12 weeks
of age the same lowbonemass/ high sympathetic activity pheno-
type than theHtr2c/ and Tph2/mice (Figure 4F and data not
shown). These results support the notion that BDS utilizes the
Htr2c receptor to regulate sympathetic tone and bone mass
independently of the influence it exerts through this receptor on
energy metabolism.
To determine whether it is through its expression in VMH
neurons that Htr2c regulates bone mass we used mutant mice
harboring a loxP-flanked transcriptional blocking (loxTB)
cassette inserted in the Htr2c gene (loxTB Htr2c mice) (Xu
et al., 2008). In these mice disruption of Htr2c transcription can
be alleviated, in a cell population of choice, by the Cre
Figure 4. Serotonin Promotes Bone Mass through Htr2c Receptors in VMH
(A–C) Analysis of axonal projections emanating from the serotonergic neurons of the brainstem. Coronal sections through the Dorsal (DR), Median (MR) raphe and
ventromedial hypothalamus (VMH) nuclei from Sert-Cre;Rosa26REcfp mice identifying serotonergic neurons and their axonal projections to VMH neurons
through Ecfp immunohistochemistry (A). Retrograde (B) and anterograde (C) Rhodamine dextran labeling (Rh-dextran) in Tph2LacZ/+ mice. Coronal sections
through the brainstem and hypothalamus showing colocalization of b-galactosidase staining and Rh-dextran fluorescence.
(D) qPCR analysis of serotonin receptor expression in hypothalamus.
(E) Double fluorescence situ hybridization analysis ofHtr2c expression with Pomc or Sf1 expression in anterior (Top panel) and posterior (Bottom panel) VMH and
arcuate nuclei. The third ventricle is outlined by a white line.
(F) Histomorphometric analysis of vertebrae of WT, Htr2c/, Htr2c+/, Tph2+/ and Htr2c+/;Tph2+/ mice.
(G and H) qPCR analysis of Ucp1 expression in brown adipose tissue (G) and epinephrine levels in urine (H) in WT, Htr2c/, and Htr2cSF1
+/+ mice.
(I) Histomorphometric analysis of vertebrae of WT, Htr2cloxTB
/ and Htr2cSF1+/+ mice.
(J) HPLC analysis of glutamate levels in hypothalamus of WT and Htr2c/ mice.
For all panels (except [J]): * p < 0.05; ** p < 0.01 (Student’s t test). Error bars represent the SEM. For (J): one-way ANOVA, Newman-Keuls test; different letters on
two or more bars indicate significant differences between the respective groups (p < 0.05).recombinase.Htr2c re-expression was targeted to VMHneurons
by crossing loxTB Htr2c mice with Sf1-Cre mice (Figure S4J).
Histological analyses showed that re-expression of Htr2c
receptor in VMH neurons (Htr2cSF1+/+ mice) rescued entirely
the bone mass phenotype observed in the absence of Htr2c
(Figures 4G–4I). Moreover, Ucp1 expression in brown fat andurinary elimination of epinephrine were also similar between
WT and Htr2cSF1+/+ mice and levels of glutamate, an inhibitor
of sympathetic tone that were suppressed in Htr2c/ hypothal-
ami were partially restored in Htr2cSF1+/+ hypothalami (Figures
4G, 4H, and 4J). These findings echo previous observations indi-
cating that serotonin attenuates activation of noradrenergicCell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc. 981
Figure 5. Leptin Inhibits Bone Mass Accrual by Inhibiting Brain-Derived Serotonin Synthesis
(A) In situ hybridization analysis and coimmunolocalization of ObRb expression in serotonergic neurons.
(B and C) qPCR analysis of Tph2 expression (B) and brainstem serotonin content (C) at different ages in WT and ob/ob female mice.
(D and E) qPCR analysis of Tph2 expression following intra-cerebroventricular (ICV) infusion of leptin at different doses (D) and at different time points (E) in
WT mice.
(F) Immunohistochemical analysis of STAT3 phosphorylation in the dorsal and median raphe following leptin ICV. Arrows indicate pSTAT3/ b-Gal positive cells.
(G and H) qPCR analysis of Tph2 expression (G) and brainstem serotonin content (H) in WT, ob/ob and ob/ob;Tph2+/ mice.
(I) Histomorphometric analysis of vertebrae of ob/ob and ob/ob;Tph2+/ mice.
(J) Representative traces of action potentials recorded from WT mice before, during and after the application of leptin (100 nM). R.M.P.: 43.0 mV.
(K and L) Analysis of serotonergic neuron action potential (AP) frequency in brainstem slices from WT (K) and ObRbSERT
/ (L) mice.
For all panels (except [D], [E], [G], [H] and [K]): * p < 0.05; ** p < 0.01 (Student’s t test). Error bars represent the SEM. For (D), (E), (G), (H), and (K): one-way ANOVA,
Newman-Keuls test; different letters on two or more bars indicate significant differences between the respective groups (p < 0.05).neurons in the locus coeruleus (Aston-Jones et al., 1991). Taken
together, the results presented so far indicate that BDS acts on
VMH neurons, through Htr2c, to decrease sympathetic activity
and thereby favors bone mass accrual.
Leptin Inhibits Bone Mass Accrual by Decreasing
Brain-Derived Serotonin Synthesis
Although leptin and serotonin exert opposite influences on bone
mass accrual, several features suggested that they might oper-
ate in the same pathway. For instance serotonin, like leptin,
uses the sympathetic tone to regulate bone mass and, also982 Cell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc.like leptin, it requires VMH neurons integrity to achieve this func-
tion. As shown below, multiple lines of evidence indicate that it
is by inhibiting BDS synthesis that leptin prevents bone mass
accrual.
First, ObRb, the signaling form of the leptin receptor, is ex-
pressed in b-galactosidase-positive Tph2-expressing neurons
(Figure 5A). Second, Tph2 expression increased steadily over
time in ob/ob mice to eventually reach a level 10-fold higher
than what is seen in WT mice at 9 months of age (Figure 5B)
and conversely, serotonin content is significantly higher in
the brainstem of ob/ob mice (Figure 5C). Third, leptin ICV
infusion decreased Tph2 expression in a time- and dose-depen-
dentmanner inWTmice (Figures 5D and 5E). Fourth, coimmuno-
localization studies revealed that the phosphorylation of Stat3,
a transcription factor mediating leptin signaling, that was
increased in b-galactosidase-positive serotonergic neurons of
the brainstem following acute leptin ICV infusion in WT mice
was dramatically reduced in ObRbSERT
/ mice (Figure 5F). In
support of these correlative arguments ob/ob mice lacking one
allele of Tph2 (ob/ob;Tph2+/ mice) displayed normal Tph2
expression, normal serotonin content in the brainstem, normal
sympathetic tone and normal bone remodeling parameters and
bone mass (Figures 5G–5I, and S5). These data suggest a model
whereby leptin regulates bone mass accrual through a double
inhibitory loop. Leptin inhibits synthesis of BDS, which in turn
reduces, by signaling in VMH neurons, the sympathetic tone;
as a result leptin prevents bone mass accrual.
Leptin Inhibits the Neuronal Activity of Serotonergic
Neurons
The mediation of peripheral hormone action on the output of the
brain relies on altered circuit activity. Interaction between
neuronal circuits hinges on electric properties of neurons,
particularly on the generation of action potentials. Thus to test
whether leptin directly alters serotonin output from brainstem
neurons, we analyzed the responses of serotonin-producing
cells to leptin with whole cell patch clamp recording in brain sli-
ces containing dorsal raphe (DR) (Supplemental Experimental
Procedures). Slices were taken from WT animals and from
mice lacking ObRb selectively in Tph2-expressing neurons
(ObRbSERT
/ mice). Serotonergic neurons were identified ac-
cording to their unique properties (long-duration action poten-
tial, activation by norepinephrine and inhibition by serotonin
itself) (Liu et al., 2002). Since serotonergic neurons are usually
quiescent in slices because of the loss of noradrenergic inputs,
action potentials in these neurons were restored by application
of alpha-1 adrenergic agonist phenylephrine (3 mM) in the bath
(Liu et al., 2002). Whole cell patch recording showed that leptin
significantly decreased action potential frequency in seroto-
nergic neurons of WT mice, but not in serotonergic neurons of
mice lacking ObRb in Tph2-expressing neurons (ObRbSERT
/
mice) (Figures 5J–5L). These data show that leptin can alter
directly activity of serotonergic neurons in the brainstem and
that this effect of leptin is mediated by ObRb expressed on
these neurons.
Brain-Derived Serotonin Regulates Appetite
and Energy Expenditure
In addition to low bone mass, we consistently observed a signif-
icant decrease in fat padweight in Tph2/mice (Figure 6A). This
surprising observation led us to analyze in greater details energy
metabolism in these mutant mice. At both 6 and 12 weeks of age
there was a significant decrease in food intake in Tph2/
(31%) and Tph2+/ (14%) mice compared to WT littermates
along with an increase in energy expenditure (as measured by
VO2, XTOT and Heat production) (Figures 6B–6E). In contrast
glucose metabolism, serum levels of leptin and other hormones
were not affected in Tph2-deficient mice (Figures 1H, S1E, S6A,
and S6B).This observation along with the fact that the control of appetite
and energy expenditure requires the integrity of the arcuate
nuclei of the hypothalamus raised the prospect that axonal
projections emanating from Tph2-expressing neurons reach
arcuate nuclei to regulate these functions. To address this ques-
tion we crossed Rosa26-Ecfp mice with Sert-cre mice and
analyzed on adjacent sections expression of Pomc-1 and Npy,
two arcuate neuron-specific genes (Figures 6F and S4B). This
analysis verified that neurons of the arcuate nuclei were targeted
by serotonergic innervations emanating from the brainstem, an
observation confirmed in the Tph2+/ mice by retrograde
labeling of the projections reaching the serotonergic neurons
of the brainstem (Figure 6F). Among all serotonin receptors the
most highly expressed in arcuate neurons were Htr1a, and, to
a lower extent, Htr2b and Htr2c (Figures 6G and S4C). While
food intake was not affected inHtr2c/mice, it was significantly
reduced in mice lacking Htr1a in all cells (24% reduction) or
lacking Htr2b in arcuate neurons only (10% reduction); fat
pad weight was also lower in Htr1a/ and Htr2bPOMC
/ mice
(Figures 6H, 6I, and S4D).
We next asked whether expression of genes expressed in
hypothalamic neurons and that may mediate leptin regulation
of appetite was perturbed in Tph2/mice. Among those tested
the only gene whose expression was significantly increased in
Tph2/ mice was Mc4r (Figure 6J), a gene whose inactivation
in mice and humans cause hyperphagia and obesity (Huszar
et al., 1997; Yeo et al., 1998). Two experimental evidences
support the notion that the appetite phenotype of the Tph2/
mice was caused, at least in part, by an increase in melanocortin
signaling. First, ICV infusion of a Mc4r antagonist (HS014)
increased appetite 50% in Tph2/ mice (Figure 6K); second
ICV infusion of a Mc4r agonist (MTII) increased c-Fos expression
in neurons of the paraventricular and arcuate nuclei of both WT
and Tph2/mice (Figures 6L andS6C). Moreover,Mc4r expres-
sion was increased 2-fold in Htr1a/ and 1.6-fold in
Htr2bPOMC
/ mice, but was unaffected in Htr2c/ mice (Fig-
ure 6J and data not shown). Energy expenditure was normal in
Htr1a/ and Htr2bPOMC
/ indicating that serotonin uses other
receptors, yet to be identified, to regulate this function (Figures
S6D–S6G). Taken together these results indicate that BDS regu-
lates appetite and energy expenditure and that for the control of
appetite this mediation occurs through the Htr1a and Htr2b
receptors and involves melanocortin signaling.
Leptin Signaling in Serotonergic Neurons Regulates
Appetite, Energy Expenditure, and Bone Mass
Three reasons led us to ask next whether the appetite and energy
expenditure phenotypes of the ob/ob mice were serotonin-
dependent. The first one is that the conjunction of a decrease
in appetite and an increase in energy expenditure is the mirror
image of what is seen inmice lacking leptin signaling; the second
one is that leptin inhibition of serotonin synthesis in the brainstem
is the mechanism used by this hormone to inhibit bone mass
accrual; the third one is that no molecular mechanisms has
been identified so far to explain the common control of bone
mass and energy metabolism.
To test this hypothesis we first used ob/ob;Tph2+/mice, that
have a normal content of serotonin in the brain (Figure 5H).Cell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc. 983
Figure 6. Serotonin Promotes Food Intake through Htr1a and Htr2b Receptors on Arcuate Neurons
(A and B) Fat pad weights (A) and food intake (B) in WT, Tph2+/ and Tph2/ mice.
(C–E) Energy expenditure in WT and Tph2/ mice; measured by volume of oxygen consumption (VO2) (C), locomotor activity (D), and heat production (E).
(F) Analysis of axonal projections emanating from the serotonergic neurons. Cross of Sert-Cre and Rosa26REcfp mice identified projections reaching
arcuate (Arc) nuclei in the hypothalamus through Ecfp immunohistochemistry colocalized to molecular markers of arcuate neurons (Pomc-1 and Npy) by
in situ hybridization. Retrograde Rhodamine dextran labeling of the arcuate neurons identified serotonergic neurons in the brainstem in Tph2LacZ/+mice through
colocalization of b-galactosidase staining and Rh-dextran fluorescence in serotonergic neurons of the brainstem.
(G) In situ hybridization analysis of Htr1a, Htr2b in Pomc1-expressing arcuate neurons of the hypothalamus. 3V: third ventricle.
(H and I) Food intake (H) and fat pad weights (I) in WT, Htr1a/, and Htr2bPOMC
/ mice.
(J) qPCR analysis of hypothalamic gene expression in WT, Htr1a/ and Htr2bPOMC
/ mice.
(K) Food intake in WT, Tph2/ mice before and after Mc4r antagonist (HS014) administration.
(L) cFos induction in paraventricular nucleus of hypothalamus in WT, Tph2/mice before and after acute administration Mc4r agonist (MTII). 3V: third ventricle.
(M–O) Volume of oxygen consumption (M), fat pad weight (N) and food intake (O) in WT, ob/ob, ob/ob;Tph2+/, and ob/ob;Tph2/ mice.
For all panels (except [A], [B], [H–J], and [M–O]): * p < 0.05; ** p < 0.01 (Student’s t test). Error bars represent SEM. For (A), (B), (H–J), and (M–O): one-way ANOVA,
Newman-Keuls test; different letters on two or more bars indicate significant differences between the respective groups (p < 0.05).Remarkably, ob/ob;Tph2+/ mice also had appetite and energy
expenditure parameters undistinguishable from WT littermates
(Figures 6M–6O and data not shown) suggesting that leptin984 Cell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc.must inhibit BDS synthesis in order to decrease appetite and to in-
crease energy expenditure. Consistent with this hypothesis ob/ob
mice unable to synthesize serotonin at all in the brain (ob/ob;
Figure 7. ObRb Expression in Serotonergic Neurons Is Necessary and Sufficient for Leptin Regulation of Bone Mass Accrual, Appetite,
and Energy Expenditure
(A) Histomorphometric analysis (vertebrae) of +/+;Sf1-Cre, ObRbSF1
/, +/+;Pomc1-Cre, ObRbPOMC
/, +/+;Sert-Cre and ObRbSERT
/ mice.
(B) qPCR analysis of Ucp1 expression in brown adipose tissue in WT, ObRbSF1
/, ObRbPOMC
/ and ObRbSERT
/ mice. WT refers to +/+;Sf1-Cre, +/+;
Pomc1-Cre or +/+;Sert-Cre.









(H) Brainstem serotonin content in WT, ob/ob, ObRbSERT
/, and ObRbSF1
/ mice.
(I) qPCR analysis in the hypothalamus in WT, ObRbSERT
/, and ob/ob mice.
(J) Diameter of Pomc-expressing cells in WT and ObRbSERT
/ mice.
(K) Model of the leptin-dependent regulation of bone mass and appetite. Leptin inhibits release of brainstem-derived serotonin, which favors bone mass accrual
and appetite. Adipocytes are in yellow; serotonergic neurons are in pink; VMH is in blue and arcuate is in green.
For all panels (except [B–F], [H], and [I]): * p < 0.05; ** p < 0.01, *** p < 0.001 (Student’s t test). Error bars represent the SEM. For (B–F), (H), and (I): one-way ANOVA,
Newman-Keuls test; different letters on two or more bars indicate significant differences between the respective groups (p < 0.05).Tph2/) had even a lower appetite than WT mice; as a result
their fat pad weights were significantly smaller than the ones of
ob/ob littermates (Figures 6M–6O).
Next, to establish that serotonergic neurons of the brainstem
and BDS are a critically important entry point and target of leptin
in the brain, we analyzed bonemass, appetite and energy expen-
diture in mouse strains lacking ObRb in distinct neuronal popu-
lations in the brain (Figures S7A and S7B). This analysis was
performed on mice fed a normal diet since leptin signaling-
deficient mice develop a massive obesity on this diet. The spec-ificity of Cre expression was verified for each mouse line by
crossing them with RosaR26 mice and by in situ hybridization
(Soriano, 1999) (Figures S7A and S7B).
As reported previously mice lacking ObRb either in Sf1-
expressing neurons of the VMH nuclei or in Pomc-expressing
neurons of the arcuate nuclei had normal sympathetic activity,
bone remodeling parameters and bone mass; they also had
normal appetite, energy expenditure and body weight (Figures
7A–7G and S7A–S7I) (Balthasar et al., 2004; Dhillon et al.,
2006). In contrast ObRbSERT
/ mice lacking ObRb inCell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc. 985
serotonergic neurons of the brainstem developed rapidly, a low
sympathetic activity, high bone mass phenotype and a similar
increase in appetite as ob/ob mice; they also had low energy
expenditure (Figures 7A–7G). As a result ObRbSERT
/ mice,
when fed a normal diet, developed an obesity phenotype of
similar severity and at a similar pace than mice lacking leptin
signaling (Figures 7G and S7E). Serotonin in the brain of Ob-
RbSERT
/ was elevated to the same extent as in ob/ob mice,
while it was normal in the brain of ObRbSF1
/ mice
(Figure 7H). Remarkably for our purpose hypothalamus gene
expression analysis by real-time PCR revealed a decrease in
Mc4r and Pomc expression, and an increase in Npy and Agrp
expression in ObRbSERT
/ mice that is of similar severity to
the one observed in ob/ob mice. (Figure 7I).
ObRb deletion in Tph2-expressing neurons also had an orga-
nizational effect on Pomc-expressing neurons of the arcuate
nuclei. Indeed, the average diameter of Pomc-expressing
neurons in ObRbSERT
/ mice (n = 42) was significantly lower
than inWTmice (Figure 7J). The lower POMCperikaryal diameter
of ob/ob mice is associated with a 50% decrease in the
number of perikaryal synapse density of POMC neurons (Pinto
et al., 2004). Altered synaptic input organization of POMC
neurons was also detected in ObRbSERT
/ mice (14.76 ± 1.3
versus 27.31 ± 2.03 synapses per 100 micron perikaryal
membrane in ObRbSERT
/ and WT mice respectively). Thus, it
is likely that the ob/ob phenotype of POMC neurons is deter-
mined, at least in part, by leptin signaling in serotonergic neurons
of the brainstem.
DISCUSSION
The results presented here demonstrate that in order to regulate
bone mass accrual, appetite and energy expenditure leptin
needs to inhibit the electrical activity and serotonin synthesis in
Tph2-expressing neurons of the brainstem (Figure 7K). These
results modify the map of leptin signaling in the brain and
indicate that the serotonergic neuronal circuitry exerts a more
fundamental influence on several homeostatic functions than
previously thought. Moreover, they identify BDS as the long
sought-after molecular basis for the common control of bone
mass and energy metabolism.
Brain-Derived Serotonin Regulation of Bone Mass
This effort to complete our understanding of the regulation of
bone mass by serotonin led to two unexpected results. The first
one is that, depending on its site of synthesis, serotonin regulates
bone mass accrual in opposite directions: it inhibits it when
synthesized in the duodenum and favors it when acting as
a neurotransmitter. To our knowledge this is the first example
of a molecule exerting different influences on bone remodeling
depending on its site of synthesis. The central function of sero-
tonin is mediated through the Htr2c receptor expressed in
VMH neurons. Htr2c/ mice are markedly osteopenic before
any metabolic modification is detectable, indicating that sero-
tonin regulation of bonemass occurs independently of its effects,
through Htr2c, on energy metabolism. Given what is known
about the molecular signaling of serotonin in osteoblasts (Yadav986 Cell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc.et al., 2008), future studies are needed to determinewhether BDS
recruits the same transcription factor(s) in VMH neurons.
The second surprising observation is that although it accounts
only for a rather small portion of the total pool of serotonin in the
body (5%) BDS influence on bone remodeling is dominant over
that exerted by gut-derived serotonin. Since BDS synthesis is
regulated by leptin these results infer that leptin regulation of
bone mass is more important than the one exerted by gut-
derived serotonin (Yadav et al., 2008). This observation along
with the fact that leptin appears during evolution with a bony
skeleton underscores the importance of the regulation of bone
remodeling in the panoply of leptin’s function; it also predicts
that using leptin as a treatment for obesity would favor appear-
ance of osteoporosis.
Patients taking chronically serotonin reuptake inhibitors
(SSRIs) have an increased risk of osteoporotic fractures (Ri-
chards et al., 2007). Consistent with this observation an animal
model reproducing this chronic use of SSRIs, namely mice lack-
ing 5-hydroxytryptamine transporter (5HTT), a molecule respon-
sible for serotonin reuptake by cells, also develop a low bone
mass phenotype (Warden et al., 2005). Surprisingly however,
this low bonemass phenotype cannot be ascribed to an increase
in circulating serotonin levels i.e., to gut-derived serotonin, since
serotonin is undetectable in the plasma of these mice (data not
shown). The low bone mass of 5Htt/ mice further supports
the notion that BDS exerts a dominant role in the regulation of
bone mass.
Serotonin Regulation of Appetite and Energy
Expenditure
The study of BDS functions led to other unexpected findings
beyond the control of bone mass. Indeed the deletion of Tph2
shows that BDS is a powerful orexigenicmolecule in vertebrates.
This function of BDS is similar to the function of serotonin in
invertebrates (Nonogaki et al., 1998; Srinivasan et al., 2008).
Genetic analysis showed that the orexigenic effect of serotonin
occurs through Htr1a and Htr2b receptors, in aMc4r-dependent
manner (Heisler et al., 2002; Lamet al., 2008). This role of Htr1a in
the regulation of appetite is consistent with the orexigenic action
of Htr1a agonists (Gilbert et al., 1988; Neill and Cooper, 1988).
The demonstration that it is through its expression in arcuate
neurons that Htr1a regulates appetite will need generation of a
cell-specific deletion of this gene.
The fact that removal of the ligand and addition of a pharmaco-
logical agonist of a receptor result in the same phenotype, i.e.,
anorexia, could have several explanations (Vickers et al.,
1999). For instance, it is possible that signaling through some
serotonin receptors may antagonize signaling through others.
Likewise, it should be noted that in most settings the effect of
pharmacologic agents are acute while by definition the effect
of gene deletion is chronic. Lastly, it is also possible that different
serotonin receptors regulate differently food intake possibly
even on the same neuron (Xu et al., 2008).
Brain-Derived Serotonin as a Target of Leptin
Several lines of evidence suggested initially that leptin regulates
bone mass, appetite and energy expenditure following binding
to its receptors located on hypothalamic neurons. Chief among
those are the facts that the hypothalamus is a known regulator of
most homeostatic functions and that ObRb is highly expressed
in various hypothalamic neuronal populations (Elmquist et al.,
2005). Surprisingly however, deletion of ObRb in those hypotha-
lamic neuronal populations did not affect any of these three func-
tions (Balthasar et al., 2004; Dhillon et al., 2006). These latter
findings suggested the following hypothesis: leptin would act
in other parts of the brain where its receptor is expressed to
affect synthesis of neurotransmitter(s), which would then act in
hypothalamic neurons. That serotonin is the initial target in the
brain of leptin regulation of bone mass accrual was an incentive
to test whether it could also be implicated in the leptin regulation
of appetite and energy expenditure.
We show here, through cell-specific gene deletion of Tph2 or
the leptin receptor, that BDS enhances appetite and decreases
energy expenditure and that leptin regulates these functions by
inhibiting BDS synthesis. Thus leptin does use the same mecha-
nism to regulate bone mass accrual, appetite and energy expen-
diture. We remain aware however, that these data do not exclude
formally the possibility that leptin acts also on hypothalamic
neurons at a level not detectable using cell-specific gene deletion
experiments. For instance, our study does not rule out an involve-
mentofAgrp-expressingneurons in thecontrol of variousaspects
of energy metabolism (van de Wall et al., 2008). This is especially
true since Agrp expression is similarly increased in ObRbSERT
/
andob/obmice.By identifyingbrainstemserotonergicneuronsas
an initial target of leptin this study provides a cellular and molec-
ular explanation for the apparent contradiction between the fact
that chemical lesioning of hypothalamic neurons hampers leptin
signaling while inactivating ObRb in these neurons does not. A
question raised by our work is to know what are the functions of
the leptin receptor expressed in hypothalamic neurons? At the
present time it seems that ObRb expression on these neurons is
mainly needed for the regulation of insulin secretion and glucose
metabolism (Coppari et al., 2005; Hinoi et al., 2008; van de Wall
et al., 2008) a function not affected by serotonin or leptin signaling
in serotonergic neurons (Figure S1). Indeed it is important to
underscore that serotonin is not implicated in all functions of lep-
tin, for instance ob/ob;Tph2+/, as ob/obmice, are sterile.
Coregulation of Bone Remodeling and Energy
Metabolism
Why would bone remodeling and energy metabolism need to be
coregulated in the first place? To answer this question, one
needs to look at what was the original purpose of bone remodel-
ing earlier during evolution. Through its ability to constantly renew
bone the original function of bone remodeling was to repair micro
and macro damages, i.e., fractures of bones. This function was,
early on, absolutely necessary to maintain mobility and therefore
to assure survival. In addition, bone remodeling is characterized
by two opposing processes: destruction followed by de novo
formation; these two cellular events are costly in terms of energy;
even more so if one takes into account that they occur simulta-
neously in multiple locations. Thus, for bone remodeling to occur
there must be a constant supply of energy channeled to osteo-
clasts and osteoblasts. This view of bone remodeling predicts
that there should be one or several hormones, appearing during
evolution with this function, and regulating it and energy metab-olism. To date leptin is the only known hormone fulfilling all these
criteria. This view of bone remodeling also implies that the meta-
bolic importance of the skeleton that begins to be unraveled
(Lee et al., 2007) has not been fully characterized yet.
EXPERIMENTAL PROCEDURES
Mice Generation
Tph2-LacZ mice were generated by embryonic stem cell manipulations
following standard protocols to obtain Tph2+/mice. Tph2+/mice were inter-
crossed to obtain the WT, Tph2+/, and Tph2/mice for analysis. Generation
of Tph1/, Htr2c/, loxTB Htr2c, Htr1a/, ObRbfl/fl, Htr2bfl/fl, Sf1-Cre, and
Sert-Cre mice was previously reported (Balthasar et al., 2004; Dhillon et al.,
2006; Klemenhagen et al., 2006; Tecott et al., 1995; van de Wall et al., 2008;
Xu et al., 2008; Yadav et al., 2008; Zhuang et al., 2005). WT, Pomc1-Cre and
ob/ob mice were obtained from The Jackson Laboratory.
Histological Procedures, Immunohistochemistry, In Situ
Hybridization, Axonal Tracing, and Microcomputed
Tomography Analysis
Sections containing dorsal raphe were from bregma 4.04 to 5.40; median
raphe from 4.04 to 4.48; caudal raphe from 4.84 to 7.48; arcuate from
1.22 to 2.80; VMH from 1.06 to 2.06 and PVN from 0.58 to 1.22
according to Franklin and Paxinos mouse brain atlas. Immunohistochemistry
was performed on paraffin-embedded specimens sectioned at 6 mm accord-
ing to standard protocols. LacZ staining was performed on whole brain and
coronal sections obtained from the Tph2+/ mice following standard proce-
dures. In situ hybridization on brain sections was performed as described
(Oury et al., 2006). Ex vivo axonal tracing was performed using Rhodamine-
conjugated dextrans (Molecular Probes, Eugene, Oregonaxonal; See Supple-
mental Experimental Procedures for details). Bone histomorphometric
analyses were performed on undecalcified sections using the Osteomeasure
analysis system (Osteometrics, Atlanta). Trabecular bone architecture of
proximal tibia was assessed using a mCT system (VivaCT 40, SCANCO
Medical AG, Switzerland) as described (Shi et al., 2008). Six to 12 animals
were analyzed for each group.
Bioassays
Serotonin levels in the brain and serum were quantified as described (Yadav
et al., 2008). Serum level of total deoxypyridinoline (DPD) cross-links was
measured using the Metra tDPD kit (Quidel corp. San Diego, CA). Urinary elim-
ination of catecholamineswasmeasured in acidified spot urine samples by EIA
(Bi-CAT, Alpco Diagnostics, Salem, NH) and creatinine (Metra creatinine kit,
Quidel corp. San Diego, CA) used to standardize between urine samples.
Molecular Studies
RNA isolation, cDNA preparation and qPCR analysis was carried out following
standard protocols (See Supplemental Experimental Procedures). Genotypes
of all the mice were determined by PCR. All primer sequences for genotyping
and DNA probes for southern hybridization are available upon request.
Electrophysiology, Food Intake, and Energy Expenditure
Measurements
Brain slice preparation and electrophysiological recording were performed as
described (Liu et al., 2002; Rao et al., 2007; Supplemental Experimental Proce-
dures). Food intake was measured using metabolic cages (Nalgene, Roches-
ter, NY) and energy expenditure by indirect calorimetry method as described
(Shi et al., 2008; Supplemental Experimental Procedures).
Statistical Analyses
Statistical significance was assessed by Student’s t test or a one way ANOVA
followed by Newman-Keuls test for comparison between more than two
groups. p < 0.05 was considered significant. Different letters indicate signifi-
cant differences among groups.Cell 138, 976–989, September 4, 2009 ª2009 Elsevier Inc. 987
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